Somewhat Positive News Coverage Somewhat Unlikely to Impact Biohaven Pharmaceutical Holding Co (BHVN) Stock Price

Media headlines about Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Biohaven Pharmaceutical Holding Co earned a news sentiment score of 0.24 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 49.5796443491143 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

These are some of the news articles that may have effected Accern Sentiment Analysis’s scoring:

Shares of Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN) traded up 11.45% during trading on Friday, reaching $28.52. 188,569 shares of the company traded hands. Biohaven Pharmaceutical Holding Co has a 12-month low of $17.00 and a 12-month high of $29.50. The stock’s market capitalization is $1.02 billion. The firm’s 50 day moving average is $25.10 and its 200-day moving average is $23.97.

A number of equities analysts have recently issued reports on BHVN shares. William Blair started coverage on shares of Biohaven Pharmaceutical Holding Co in a research report on Tuesday, May 30th. They set an “outperform” rating and a $46.00 price objective on the stock. Barclays PLC assumed coverage on shares of Biohaven Pharmaceutical Holding Co in a research report on Tuesday, May 30th. They set an “overweight” rating and a $30.00 price objective on the stock. Piper Jaffray Companies assumed coverage on shares of Biohaven Pharmaceutical Holding Co in a research report on Tuesday, May 30th. They issued an “overweight” rating and a $21.00 price target on the stock. Morgan Stanley assumed coverage on shares of Biohaven Pharmaceutical Holding Co in a research report on Wednesday, May 31st. They issued an “overweight” rating on the stock. Finally, Needham & Company LLC assumed coverage on shares of Biohaven Pharmaceutical Holding Co in a research report on Tuesday, May 30th. They issued a “buy” rating and a $30.00 price target on the stock. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $31.75.

COPYRIGHT VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Biohaven Pharmaceutical Holding Co (BHVN) Stock Price” was originally posted by Rincon Hill News and is the property of of Rincon Hill News. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://rinconhillneighbors.org/2017/08/19/biohaven-pharmaceutical-holding-co-bhvn-receives-media-impact-rating-of-0-24-updated-updated.html.

Biohaven Pharmaceutical Holding Co Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Receive News & Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related companies with our FREE daily email newsletter.

 

Latest News



Leave a Reply

 
© 2006-2017 Rincon Hill News.